These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37801234)

  • 1. Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients.
    Shah B; Chen JMH; Wu JJ; Feng C; Zhou L; Park JE; Hadjiivassileva T; Kerbauy FR; Wade SW; Keeping S
    Adv Ther; 2023 Dec; 40(12):5383-5398. PubMed ID: 37801234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
    Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
    Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
    Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Song J; Ma Q; Gao W; Cong Z; Xie J; Zimmerman Z; Belton L; Franklin J; Palmer S
    Adv Ther; 2019 Apr; 36(4):950-961. PubMed ID: 30758745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
    Shah BD; Cassaday RD; Park JH; Houot R; Oluwole OO; Logan AC; Boissel N; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff PJ; Jeyakumar D; Mao D; Adhikary S; Zhou L; Schuberth PC; Damico Khalid R; Ghobadia A
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.
    Minnema MC; Yin X; Davi R; Keeping S; Park JE; Itani T; Hadjivassileva T; Castaigne JG; Damico Khalid R; Zhou L; Wu JJ; Shah BD
    Leuk Lymphoma; 2024 May; ():1-10. PubMed ID: 38785408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
    Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
    Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma.
    Anderson MK; Torosyan A; Halford Z
    Ann Pharmacother; 2022 May; 56(5):609-619. PubMed ID: 34340597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
    Wang Y; Jain P; Locke FL; Maurer MJ; Frank MJ; Munoz JL; Dahiya S; Beitinjaneh AM; Jacobs MT; Mcguirk JP; Vose JM; Goy A; Andreadis C; Hill BT; Dorritie KA; Oluwole OO; Deol A; Paludo J; Shah B; Wang T; Banerjee R; Miklos DB; Rapoport AP; Lekakis L; Ghobadi A; Neelapu SS; Lin Y; Wang ML; Jain MD
    J Clin Oncol; 2023 May; 41(14):2594-2606. PubMed ID: 36753699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
    Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
    Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Dong J; Adhikary S; Zhou L; Schuberth PC; Faghmous I; Masouleh BK; Houot R
    J Hematol Oncol; 2022 Dec; 15(1):170. PubMed ID: 36494725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
    Bouchkouj N; Lin X; Wang X; Przepiorka D; Xu Z; Purohit-Sheth T; Theoret M
    Oncologist; 2022 Oct; 27(10):892-899. PubMed ID: 35983953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
    Hess G; Dreyling M; Oberic L; Gine E; Zinzani PL; Linton K; Vilmar A; Jerkeman M; Chen JMH; Ohler A; Stilgenbauer S; Thieblemont C; Lambert J; Zilioli VR; Sancho JM; Jimenez-Ubieto A; Fischer L; Eyre TA; Keeping S; Park JE; Wu JJ; Nunes A; Reitan J; Wade SW; Salles G
    Leuk Lymphoma; 2024 Jan; 65(1):14-25. PubMed ID: 37840282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
    Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
    Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M
    Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.
    Stelljes M; Advani AS; DeAngelo DJ; Wang T; Neuhof A; Vandendries E; Kantarjian H; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e836-e843. PubMed ID: 35643855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
    Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
    Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
    Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
    Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.